Hutchmed (China) Limited Grant of Share Options and Awards under LTIP (7416V)
15 Décembre 2021 - 10:44AM
UK Regulatory
TIDMHCM
RNS Number : 7416V
Hutchmed (China) Limited
15 December 2021
Grant of Share Options under Share Option Scheme and Awards
under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday ,
December 15 , 2021: HUTCHMED (China) Limited ("HUTCHMED")
(Nasdaq/AIM: HCM; HKEX: 13) announces that on December 14, 2021 ,
it granted share options under the Share Option Scheme adopted by
HUTCHMED in 2015 as refreshed in April 2020 (the "Share Option
Scheme") and conditional awards ("LTIP Awards") under the Long Term
Incentive Plan adopted by HUTCHMED in 2015 ("LTIP") .
Aimed at attracting and retaining top talent, the Remuneration
Committee of HUTCHMED appointed an independent advisor to conduct a
compensation benchmarking research on peer group U.S. and China
biotech companies. The Remuneration Committee comprehensively
reviewed the compensation and share-based incentives policies of
HUTCHMED and its subsidiaries (the "Group") and established an
attractive policy to ensure the Group is able to recruit and retain
top talent. Vesting of share-based awards under the policy is in
line with that peer group.
HUTCHMED granted share options under its Share Option Scheme to
Dr Weiguo Su (Executive Director and Chief Scientific Officer of
the Company) and 14 other employees to subscribe for a total of
808,940 Ordinary Shares represented by 161,788 American Depositary
Shares ("ADSs") (each equating to five Ordinary Shares) subject to
the acceptance of the grantee.
Details of such share options granted prescribed are as
follows:
Date of grant : December 14, 2021
Exercise price of share options : US$35.21 per ADS (equivalent to
granted HK$54.93 per Ordinary Share at the
conversion rate HK$7.8=US$1) (such
exercise price has been determined
by reference to the price of the
Ordinary Shares on The Stock Exchange
of Hong Kong Limited ("HKEX " ))
Number of share options granted : 808,940 represented by 161,788 ADSs
(five share options shall entitle
the holder thereof to subscribe
for one ADS)
Closing market price of ordinary : US$35.00 per ADS (equivalent to
shares at HKEX on the date of HK$54.60 per Ordinary Share at the
grant conversion rate HK$7.8=US$1)
Validity period of the share : From December 14, 2021 to December
options 13, 2031
Vesting period of the share options : The share options will vest at 25%
on each of the first, second, third
and fourth anniversaries of the
date of grant of share options.
Among the share options granted, 24,930 share options
represented by 4,986 ADSs were granted to Dr Weiguo Su (Executive
Director and Chief Scientific Officer of the Company), being a
person discharging managerial responsibility under the UK Market
Abuse Regulation.
At the same time, HUTCHMED also granted two employees of the
Group with non-performance based LTIP Awards.
The notification set out below is provided in accordance with
the requirements of the UK Market Abuse Regulation.
Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Option over American Depositary Share (each equating
instrument to five Ordinary Shares of US$0.10)
Identification code Option over American Depositary Share with ADS ISIN:
US44842L1035
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of options in respect of 24,930 Ordinary Shares
represented by 4,986 ADSs under the
Share Option Scheme.
The share options granted are exercisable subject to
a vesting schedule of 25% on each of
the first, second, third and fourth anniversaries of
the effective date of grant.
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 4,986
-----------------
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2021-12-14
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -------------------------------------------------------
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has more than 4,500 personnel across all
its companies, at the center of which is a team of over 1,400 in
oncology/immunology. Since inception it has advanced eleven cancer
drug candidates from in-house discovery into clinical studies
around the world, with its first three oncology drugs now approved
and marketed in China. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
Forward - Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
HUTCHMED's filings with the U.S. Securities and Exchange
Commission, on AIM and on HKEX. HUTCHMED undertakes no obligation
to update or revise the information contained in this announcement,
whether as a result of new information, future events or
circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFFDSUIEFSEDE
(END) Dow Jones Newswires
December 15, 2021 04:44 ET (09:44 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
